Learn More
Gibco™ Human Artemin, Animal-Free Recombinant Protein, PeproTech®
Recombinant Protein
Supplier: Gibco™ AF45017100UG
Description
The functional human Artemin ligand is a disulfide-linked homodimer of two 12.0 kDa polypeptide monomers. Each monomer contains seven conserved cysteine residues, one of which is used for interchain disulfide bridging and the others are involved in intramolecular ring formation known as the cysteine-knot configuration.Recombinant Human Artemin is a 24.2 kDa, disulfide-linked homodimer formed by two identical 113 amino acid subunits. This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis
The protein encoded by this gene is a member of the glial cell line-derived neurotophic factor (GDNF) family of ligands which are a group of ligands within the TGF-beta superfamily of signaling molecules. GDNFs are unique in having neurotrophic properties and have potential use for gene therapy in neurodegenerative disease. Artemin has been shown in culture to support the survival of a number of peripheral neuron populations and at least one population of dopaminergic CNS neurons. Its role in the PNS and CNS is further substantiated by its expression pattern in the proximity of these neurons. This protein is a ligand for the RET receptor and uses GFR-alpha 3 as a coreceptor. Multiple transcript variants encoding different isoforms have been found for this gene.Specifications
| Q5T4W7 | |
| protein with no preservative | |
| 24.2 kDa | |
| 100 μg | |
| RUO | |
| Artemin; ARTN; Enovin; EVN; NBN; neublastin; neurotrophic factor | |
| ARTN | |
| Recombinant | |
| -20°C | |
| Lyophilized |
| Functional Assay | |
| 9048 | |
| Human Artemin, Animal-Free | |
| E. coli | |
| <0.1 EU/ μg | |
| Artemin | |
| Unconjugated | |
| AGGPGSRARA AGARGCRLRS QLVPVRALGL GHRSDELVRF RFCSGSCRRA RSPHDLSLAS LLGAGALRPP PGSRPVSQPC CRPTRYEAVS FMDVNSTWRT VDRLSATACG CLG | |
| E. coli | |
| ≥ 98% by SDS-PAGE gel and HPLC analyses. |